Clinical Trials Directory

Trials / Completed

CompletedNCT05385718

Ezra Faster Scan Study

Status
Completed
Phase
Study type
Observational
Enrollment
694 (actual)
Sponsor
Ezra AI, Inc. · Industry
Sex
All
Age
18 Years
Healthy volunteers
Accepted

Summary

The Ezra Faster Scan study uses non-invasive magnetic resonance imaging (MRI) technology that can "visually" detect early and late-stage cancer, and other pathologies. MRIs use a magnetic field and radio waves to create a 3-dimensional (3D) image of an individual's body without using ionizing radiation. The purpose of this research is to decrease the amount of time required by an individual to complete an early cancer screening comprehensive magnetic resonance imaging (MRI) scan, such as the Ezra Full Body MRI imaging scan. If the time required to conduct a comprehensive scan is reduced, the cost of the scan may also decrease. By decreasing consumer costs and time, more individuals may be able to afford MRI-based early cancer screening technology. Participants in this study will undergo a minimum 30-minute MRI session. These sessions will be used to evaluate new MRI "instructions" that allow for a faster MRI scan time. The images will also be used to develop mathematical models or machine learning tools that allow images to be enhanced. By enhancing images using machine learning, they may be restored to a quality typically observed in MRI sessions with longer scan (acquisition) times. To read more about the study, potential participants may review the informed consent form located below in the References section. Potential participants may email research.fasterscan@ezra.com, or call 516.340.1221. See study Eligibility Criteria below.

Conditions

Interventions

TypeNameDescription
OTHERMagnetic Resonance ImagingParticipants are required to undergo a non-invasive magnetic resonance imaging (MRI) scan approximately 30 minutes in length.

Timeline

Start date
2022-06-01
Primary completion
2025-02-24
Completion
2025-02-24
First posted
2022-05-23
Last updated
2025-03-03

Locations

5 sites across 1 country: United States

Source: ClinicalTrials.gov record NCT05385718. Inclusion in this directory is not an endorsement.